Paul Goudreau, executive director & head of Phase IV Solutions at the CRO Covance, recently told Scrip, “an ongoing and wide-ranging discussion is needed about assessment, payment and reimbursement of innovative products, as well as the evidence that supports them.”
Author: Informa Pharma Intelligence
Published: 02 August 2019
Number of pages:3
As more gene therapies outside the oncology and rare disease space come to the market, strategies for paying for these expensive treatments are set to evolve. Treatments with larger patient populations and wider usage are likely to come with lower prices than rare disease or oncology gene therapies, yet prices are likely to be relatively high compared with other new medicine because of the greater development costs associated with gene therapies, according to Paul Goudreau, executive director & head of Phase IV Solutions at the CRO Covance. Scrip looks at how stakeholders are considering how to move forward in terms of paying for expensive new therapies.
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.